Introduction {#S2}
============

Prodrug strategies have been widely used to address delivery problems with pharmaceuticals.^[@R1]^ Essentially all such approaches have one goal, i.e. to deliver the drug to the desired location at a sufficiently high concentration. Prodrug efforts focused on improving physicochemical properties allow for enhanced permeability and solubility. Site-selective activations allow for targeting based on environmental factors such as pH,^[@R2]^ unique redox chemistry including levels of H~2~O~2,~^[@R3]^ glutathione^[@R4]^ and other thiol species,^[@R5]^ and elevated levels of enzymes such as esterases,^[@R6],\ [@R7]^ proteases,^[@R8]^ and phosphatases.^[@R9]^ In addition, gut bacteria also present unique redox chemistry and an active enzymatic environment for site-selective targeting.^[@R10]^ In recent years, targeted drug delivery has quickly gained attention with some remarkable success, especially in the field of cancer with the goal being minimizing toxicity.^[@R11]^ For example, antibody-drug conjugates (ADC) allow for targeted delivery of drugs to the desired site.^[@R12],\ [@R13]^ There are many other targeting molecules that can be used to hone in on biomarkers such as the high affinity folate receptor,^[@R14]^ carbohydrate biomarkers,^[@R15]^ and prostate-specific membrane antigen (PSMA).^[@R16]^ Such targeted approaches work very well in enriching the concentration of the drug conjugates and prodrugs at the desired site. However, targeted release after enrichment is still a significant challenge.

Herein we describe a novel concentration-sensitive platform approach to prodrug activation based on controls by reaction kinetics using bioorthogonal click chemistry, which has been applied in prodrug preparation with excellent success.^[@R12],\ [@R17],\ [@R18],\ [@R19],\ [@R20],\ [@R21],\ [@R22],\ [@R23],\ [@R24],\ [@R25]^ Ideally, one would like to use linker chemistry that tethers the active drug to the targeting molecule in a stable fashion, and allow for selective cleavage at the desired site of action.^[@R20],\ [@R26],\ [@R27],\ [@R28],\ [@R29]^ Through the use of click chemistry and the concept of co-localization,^[@R30],\ [@R31]^ the linker can be very stable until enrichment-triggered release (ETR). The applicability of the approach is not limited to cell surface as in the case of antibody-mediated delivery (or ADC) because of the use of small molecules for both targeting and cleavage.

Results and Discussion {#S3}
======================

To establish the proof of concept, we designed two pairs of prodrug-release trigger partners that can undergo a bioorthogonal reaction with tunable release rates, which should set the stage for subsequent release of a drug moiety. As for the drug moiety, we chose two biologically and clinically relevant agents, the chemotherapeutic genotoxin doxorubicin (Dox) and the gasotransmitter carbon monoxide (CO), as model drugs. These two examples represent drugs of distinctly different properties and delivery challenges. Doxorubicin and CO have IC~50~ values generally in the range of low micromolar to high nanomolar concentrations depending on the cell lines used and drug exposure time. In the first pair of prodrug-trigger partners, we used the tetrazine-cyclooctyne chemistry as the prodrug-trigger pair for the click reaction,^[@R32],\ [@R33]^ a lactonization reaction of the cycloaddition intermediate for drug release,^[@R34]^ and mitochondria-targeting as a way to achieve enrichment, which is discussed later.^[@R35]^ Specifically, tetrazines are known to react with transcyclooctene^[@R36],\ [@R37]^ and strained cyclooctyne^[@R32],\ [@R33]^ with second order rate constants ranging from 0.0001 M^−1^s^−1^ to more than 1000 M^−1^s^−1^. As a proof of principle study, we contemplated a scenario where the prodrug could be used at a concentration of 10 μM in cell culture without cytotoxicity until triggered release is achieved based on control by reaction kinetics. For this design, we desire the second order rate constant to be below 0.25 M^−1^s^−1^, which would result in the first half-life being over 100 h without enrichment at 10 μM. Triphenylphosphine conjugation is known to enrich its "payload" to about 500 μM or higher in mitochondria,^[@R35],\ [@R38]^ which would lead to a decrease in its first half-life to about 2.2 h. What this means is that the prodrug would be non-toxic to cells until enrichment-triggered release. The general idea is presented in [Figure 1](#F1){ref-type="fig"}, which depicts a trigger-prodrug pair going through targeted enrichment, reaction kinetics-controlled click reaction, and spontaneous cyclization-based release. For the second pair of prodrug-trigger partners, we used cyclopentadienone-strained alkyne chemistry for the controlled release rates and mitochondria-targeting as a way to achieve enrichment. The reaction kinetics issues are the same as for the first one. Below, we separately described these two systems and *in vivo* demonstration of proof of principle.

The click, cyclization and release (CCR) system {#S4}
-----------------------------------------------

First, we studied the chemical feasibility of the first system using Dox as a model drug. Thus, we synthesized the two components of this drug release system: alkyne triggers (AT, **1--3**) with an appropriately positioned hydroxyl group to initiate lactonization, model tetrazine-prodrugs (TP, **4** and **5**), and tetrazine-linked prodrugs of Dox (**6** and **9**; [Table 1](#T1){ref-type="table"}). The reason that we also prepared a tetrazine conjugate (**5**) with dansyl amine was to take advantage of the strong fluorescence of dansyl amine as a marker to easily monitor and also check feasibility of the click, cyclization and release (CCR) sequence of events for amine containing prodrugs.

As the first step, we studied the basic chemical feasibility of the proposed approach. Thus, we treated 25 μM of the prodrugs **5** or **6** with alkynes **1**, **2** or **3** at different concentrations at room temperature (r.t.) or 37 °C respectively, and monitored prodrug consumption and the release of the parent drug by HPLC ([Table 1](#T1){ref-type="table"}). There are three issues in this study: i.) cycloaddition regiochemistry, ii.) substituent effect at the R~1~ position, and iii.) the effect of the "drug" on the reaction rates and regiochemistry.

On the issue of regiochemistry, one can see from [Table 1](#T1){ref-type="table"} that the cycloaddition chemistry has two possible regioisomeric products, but only one would lead to lactonization and drug release. For the strategy to work, it is critical that the correct regioisomer (**7b**) is the predominant product. Fortuitously, it was found that more than 80% Dox or dansyl amine was released within 48 h of the prodrug treatment with alkyne **2** or **3**. Such results indicate that the regiochemistry of the Inverse Electron Demand Diels-Alder reaction (DA~inv~) is such that it favors the reaction leading to **7b** with the hydroxyl group on the cyclooctyne positioned on the same side of the amide group linked to the parent drug. This allows for subsequent lactonization and drug release. To acquire initial insight into the observed regiochemistry, we performed theoretical calculations. Specifically, we used reported methods to calculate possible transition state(s) and activation energies for two regio-isomers (See [supplementary Fig. 3](#SD1){ref-type="supplementary-material"}).^[@R32]^ Schematic representations of the energy profiles for the tetrazine alkyne reactions are shown in [supplementary Fig. 3](#SD1){ref-type="supplementary-material"}. To simplify the calculation process, we used tetrazine **10** and alkyne **2** as models.^[@R32]^ The results showed that the activation energy for the first step of the DA~inv~ between **10** and **2** via transition state **TS1b** is 17.1 kcal·mol^−1^ as compared to 19.0 kcal·mol^−1^ for the reaction via transition state **TS1a**. The qualitative difference in activation energy correlates well with our observed regiochemistry outcome.

There are several reasons that we needed to understand the effect of the R~1~ group on the alkyne trigger for this project. First, we are interested in understanding factors that would allow us to tune the reaction rate. It is easy to intuitively understand that the R~1~ group would have an effect on both the DA~inv~ reaction and the subsequent lactonization. Second, for eventual applications, we need to conjugate both the tetrazine and alkyne to a targeting moiety. This means that we need a "handle" for such conjugation chemistry. For the tetrazine part, this can be easily accomplished through the phenolic hydroxyl group. For the cyclooctyne, we need to introduce an additional "handle" for such conjugations. For this reason, the R~1~ group is essential as a handle for further conjugation. Thus, we need to understand the substituent effect at this position. It was found that a methyl group or a benzyl group significantly reduced the rate of the DA~inv~ reaction. For example, when R~1~ was a hydrogen, the second order rate constant was 0.25 M^−1^s^−1^ at r.t and 1.9 M^−1^s^−1^ at 37 °C when dansyl amine-prodrug **5** was used. In comparison, the second order rate constant was 0.0075 M^−1^s^−1^ and 0.021 M^−1^s^−1^ at r.t and 37 °C, respectively, for alkyne **2** with a methyl substituent; and 0.042 M^−1^s^−1^ and 0.14 M^−1^s^−1^ at r.t and 37 °C, respectively, for alkyne **3** with a phenyl substituent. Such results indicate that the DA~inv~ reaction rates can easily be tuned over a range of more than 30-fold by using different R~1~ groups on the alkyne. Additionally, varying the temperature from r.t to 37 °C can afford another 3- to 10-fold of reaction rate variations. Besides, the reaction rate (0.25 M^−1^s^−1^) between **9** and **3b** is similar to that for the reaction between **6** and **3a** (0.17 M^−1^ s^−1^), confirming that the introduction of the TPP moiety would not significantly affect the reaction kinetics. As discussed earlier, the second order rate constant was targeted to be below 0.25 M^−1^s^−1^. The range of second order rate constants that can be tuned falls exactly where needed. It should also be noted that the R~1~ substituent accelerated the rate of the lactonization, as expected due to added conformational constraints. Therefore, all the reaction studies thus far clearly demonstrate one thing, i.e., the designed CCR system can be used for prodrug release for the intended purpose.

Regarding the third issue of the effect of the "drug" moiety on the reaction outcomes, it was found that dansylamine-prodrug **5** and Dox-prodrug **6** did not show statistically significant differences in terms of reaction rates. For example, the second order rate constant for the reaction of alkyne **1** with tetrazine **5** or **6** at 37 °C is 1.9 or 2.1 M^−1^s^−1^, respectively. Similarly, the second order rate constant for the reaction of alkyne **3b** with tetrazine **5** or **6** at 37 °C is 0.14 or 0.19 M^−1^s^−1^, respectively. Such results are expected since the "drug" portion is positioned away from all reaction centers, and thus would not be expected to have a major effect on reaction rates. The only issue is that if the lactonization rate is slow, it may only lead to partial drug release within a reasonable period of time. This is the case with alkyne trigger **1.** For example, only 60% dansylamine and 20% Dox was detected after treating prodrugs with alkyne **1** (1 mM) for 48 h. This low percentage Dox recovery was likely because of the slow lactonization rate of **7b** (t~1/2~ = 24 h) when R~1~ was hydrogen, and decomposition of Dox in PBS (t~1/2~= 50 h).^[@R39]^ In contrast, with alkyne **2,** the lactonization rate was so fast that the HPLC method did not detect the accumulation of the intermediate (CI). This also led to 85--90% release of the active drug at the 48-h point. For alkyne **3**, the situation was similar with 80--90% drug release. All such results indicate the importance of the R~1~ group not only for tethering a targeting molecule, but also for an improved lactonization rate.

In addition to the three chemical feasibility issues discussed above, we were also interested in understanding the stability of the tetrazine-linked prodrugs in the presence of high concentrations of thiol species, due to the electron deficient nature of the tetrazine moiety. It is important to note that we did not encounter stability problems ([Supplementary Table 4](#SD2){ref-type="supplementary-material"}).

In vitro assessment of the CCR system {#S5}
-------------------------------------

Next, we were interested in testing the drug delivery system in a cellular environment. We first chose the alkyne **1** and **3b**. HeLa cells were incubated with different concentrations of Dox-prodrug and alkynes, or doxorubicin, for 48 hours at 37 °C. The IC~50~ values are shown in [Table 2](#T2){ref-type="table"}. After modification, the Dox-prodrug **6** lost its activity with IC~50~ well over 100 μM, while the IC~50~ of the parent drug Dox was about 1.0 μM. Such results were expected and desirable because the activity of the prodrug means that it would not be cytotoxic before Dox is released through the CCR process. As designed, the IC~50~ of Dox-prodrug **6** is about 1.5 μM in the presence of 50 μM alkyne **1** and 2.0 μM in the presence of 50 μM alkyne **3b**. Such results indicate efficient release of the parent drug, Dox, by alkynes **1** and **3b**.

Having established a well-defined release system, we next examined the feasibility of using reaction kinetics to control drug release. Our goal was thus to target and enrich the prodrug at a particular location within the mammalian cell. It is well-known that folic acid, Arg-Asp-Asp (RGD), and many other molecules can target cancer, and be used for drug delivery.^[@R1]^ We chose mitochondrion-targeting through the use of a well-known triphenylphosphonium (TPP) moiety, which is known to enrich in mitochondria by approximately 100 to 500 fold.^[@R38]^ We elected to use mitochondria targeting because this can easily be assessed in a cell culture system. Thus, we conjugated the tetrazine prodrug and the alkyne trigger with triphenylphosphine to give **9** and **3b**, respectively. HeLa cells were treated with 10 μM or 20 μM TPP-alkyne **3b** and various concentrations of TPP-Dox-prodrug **9** (0, 1.2, 2.5, 5 and 10 μM) for 48 hours. It is clear that the IC~50~ (\~1.5 μM) for TPP-Dox **9** in the presence of 20 μM of TPP-alkyne **3b** is much lower than that of its non-TPP conjugated counterpart Dox prodrug **6** (\~10 μM) in the presence of 20 μM alkyne **3a** ([Figure 2a](#F2){ref-type="fig"}). We see a similar trend when the alkyne concentration was decreased to 10 μM. For example, the IC~50~ for TPP-Dox prodrug **9** was about 2 μM in the presence of **3b**, while the IC~50~ for Dox prodrug **6** was well over 10 μM in the presence of 10 μM of the alkyne trigger **3a** ([Figure 2b](#F2){ref-type="fig"}). As controls, both the IC~50~ values of **9** and **3b** alone are higher than 40 μM, and the treatment of 20 μM of alkyne **3a** or **3b** alone had no effect on cell viability. Such dose-dependent results strongly support the underlying hypothesis that conjugation with TPP (**3b** and **9**) allows for the enhanced release of Dox through enrichment of the prodrug in mitochondria, which subsequently led to an enhanced bimolecular reaction rate and facilitated CCR-mediated activation of the prodrug. Without such enrichment, the reaction is expected to be slow, resulting in a lower level of active Dox being released. Specifically, the second order rate constant of the reaction between the Dox-prodrug **6** and alkyne **3a** was determined to be 0.17 M^−1^s^−1^, with the first half-life at 10 μM concentration of **6** and 10 μM concentration of **3a** being about 163 h. Such results also mean that only 22% of the drug is released at the 48-h time point. If the concentrations of both the tetrazine prodrug (**9**) and alkyne (**3b**) are enriched to 500 μM in the mitochondria, the first half-life of the reaction would be 2.0 h (confirmed by experiments), which means almost complete Dox release at the 48-h time point. As a consequence, major differences in the apparent potency of the two prodrugs were observed with and without conjugation to TPP. Therefore, we conclude that enrichment in the mitochondria indeed led to triggered release of the drug, as designed. The same concept is applicable to the delivery of drugs through other targeting approaches such as receptor-mediated drug delivery.

The CO delivery system via click chemistry {#S6}
------------------------------------------

In order to demonstrate the general applicability of the "enrichment to release" concept for prodrug activation, we designed a second system, which uses different chemistry and a different "drug" component. Specifically, we designed a bioorthogonal reaction "cyclopentadienone-alkyne" pair for the targeted delivery of carbon monoxide (CO) to mitochondria ([Table 3](#T3){ref-type="table"}). CO has been widely accepted as an endogenous signaling molecule with potent physiologic and therapeutic importance on par with that of nitric oxide.^[@R40],\ [@R41],\ [@R42],\ [@R43],\ [@R44],\ [@R45]^ Mitochondria have been proposed to be a major site for action for CO.^[@R46]^ Indeed, Motterlini and Foresti have developed metal-based CO-releasing molecules (CORMs) that release CO extracellularly, rapidly diffuse into the cell, and influence mitochondrial function in part by binding to their heme-containing oxidases on the inner membrane.^[@R46],\ [@R47]^ Later on, organic CO prodrugs were reported with the ability to release CO extracellularly.^[@R17],\ [@R23],\ [@R48]^ Thus, targeting mitochondria would allow for CO release at the site of action. Given its high diffusivity, CO should be able to subsequently traverse out of the mitochondria into the cytosol to modulate additional functional effects. Previously, we successfully developed metal-free CO prodrugs by employing the click reaction between cyclopentadienone and a strained alkyne (e.g. BCN).^[@R18]^ For mitochondrial targeted delivery, we conjugated both components of the Diels-Alder reactants with TPP as the targeting moiety for mitochondria for ETR ([Table 3](#T3){ref-type="table"}).^[@R49]^ Additionally, in order to facilitate visualization of intracellular click reaction and CO release, a naphthalene group was attached to the 3, 4 position of the dienone ring to enable the fluorescence "turn-on" upon clicking these two components.^[@R23]^ Therefore, compounds **21** and **22** were readily synthesized ([Table 3](#T3){ref-type="table"}). With those compounds in hand, we initially confirmed CO release from the click reaction between **21** and **22** using the widely-accepted CO-myoglobin assay ([Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}). We next tested their second order rate constants by monitoring the blue fluorescence of the click products. Much like the previous CCR system, the ligation of TPP did not significantly affect the reaction kinetics between the alkyne and dienone compound ([Table 3](#T3){ref-type="table"}).

We next probed whether compound **21b** and **22b** could be employed for targeted delivery of CO to mitochondria. In this case, the "enrichment and release" process can be conveniently monitored by fluorescence "turn-on" upon the click reaction.^[@R17],\ [@R23]^ To test this, RAW264.7 macrophages were co-treated with **21b** and **22b** simultaneously at different concentrations at 1 and 5 μM for 3 h and imaged under the DAPI channel (absorption at 358 nm and emission at 461 nm). RAW264.7 cells co-treated with **21a** and **22a** as controls.

As shown in [Figure 3](#F3){ref-type="fig"}, RAW 264.7 cells co-treated with **21a** and **22a** showed no fluorescence signal at either 1 μM or 5 μM indicating that intracellular CO release did not occur or was undetectable by this method. In contrast, RAW cells treated with **21b** and **22b** showed strong blue fluorescence in a dose-dependent fashion ([Figure 3c--d](#F3){ref-type="fig"}), indicating CO release. The cells treated with either **21b** or **22b** alone showed no fluorescence (data not shown). In the case of the reaction between **21a** and **22a**, the first half-life was roughly calculated to be around 397 h with an initial concentration of 5 μM. Therefore, it was not surprisingly that cells treated with **21a** and **22a** for 3 h did not show any fluorescence. However, after conjugation with TPP, compounds **22b** and **21b** can be enriched in the mitochondria, and hence the local concentration for **22b** and **21b** is substantially increased. Assuming that the concentration of compound **21b** and **22b** was enriched to 400 μM, we determined the half-life for the click reaction to be around 2 h. Consequently, one would expect that cells treated with **21b** and **22b** to show strong blue fluorescence. The observed results are consistent with such analysis. In order to further confirm that CO release primarily occurred in mitochondria, RAW 264.7 cells were co-treated with **22b** (5 μM) and **21b** (2.5 μM) for 4 h, followed by addition of the mitochondrial tracker MT-deep red for 20 minutes and then imaged by confocal microscopy. As shown in [Figure 3e--h](#F3){ref-type="fig"}, the blue fluorescence (adjusted to green for ease of visualization) resulted from the click reaction between **21b** and **22b** clearly co-localized with the MT-deep red mitochondrial tracker. Collectively, the results are consistent with CO release from the enrichment of **21b** and **22b** within mitochondria.

Assessment of the CO-prodrug's ability to exert anti-inflammatory *effects in vitro* {#S7}
------------------------------------------------------------------------------------

Having confirmed that compounds **21b** and **22b** can be employed for selective targeting of CO to mitochondria through an "enrichment and release" process, we next examined if such a strategy would be effective in recapitulating CO-associated biological responses.^[@R17],\ [@R18],\ [@R23]^ Therefore, RAW 264.7 macrophages were pretreated with compounds **21b** and **22b** at different concentrations for 4 h, and then challenged with bacterial lipopolysaccharide (LPS; 1 μg/mL) for 1 h. No decrease in cell viability was observed throughout the experiment. Cell supernatants were collected for TNF expression determination by ELISA. The cells treated with **21a** and **22a**, or either compound **21b** or **22b** alone were used as negative controls. Unlike co-treatment with **21a** and **22a**, co-treatment of **21b** and **22b** dose-dependently suppressed LPS-induced TNF expression. Importantly, no effects on TNF production was observed for RAW 264.7 cells treated with **21a** and **22a** (without TPP conjugation) ([Supplementary Fig. 11](#SD1){ref-type="supplementary-material"}). These data make clear that the observed TNF suppression was associated with the presence of CO generated upon clicking **21b** with **22b** in the mitochondria. The inhibition of TNF by this mechanism of CO exposure mimicked that observed with gaseous CO as reported in numerous earlier literature reports.^[@R17],\ [@R23],\ [@R48],\ [@R50],\ [@R51]^ Furthermore, the remarkably low IC~50~ value (\~5 μM) is the lowest we have seen of all the organic CO-prodrugs tested under the same experimental protocols.^[@R17],\ [@R18]^ For example, with organic CO-prodrugs, we have seen IC~50~ values in the 25--100 μM range depending on the release half-life (ranging from 2 min-2 h). Of particular importance is the nearly complete suppression of TNF production at 10 μM ([Supplementary Fig. 11](#SD1){ref-type="supplementary-material"}), which has not been observed with any previously tested organic CO-prodrugs.^[@R17],\ [@R18]^ Such results further suggest the power of directly delivering CO to mitochondria.

Assessing the utility of the enrichment-triggered release system *in vivo* {#S8}
--------------------------------------------------------------------------

To assess whether the concept of enrichment--triggered release would work *in vivo* and result in the intended pharmacological effect, we tested the CO-prodrug system in a well-characterized *in vivo* model of acetaminophen (APAP)-induced acute liver injury where TNF is known to be involved and where inhaled CO gas has been shown to impart salutary effects when given after APAP and at a time when liver injury has already begun.^[@R52],\ [@R53],\ [@R54]^ In this model, fasted male CD-1 mice were administered an overdose of APAP, which leads to rapid pro-inflammatory sequelae ultimately resulting in massive hepatocyte cell death ([Figure 4](#F4){ref-type="fig"}). We reasoned that the described CO-prodrug should match the hepatoprotection observed with inhaled CO. APAP injury occurs in two phases, the first is a rapid radical-mediated hepatocyte cell death that releases local inflammatory mediators. The second phase that ultimately leads to liver failure is a cytokine storm that results in massive hepatocyte death and has systemic implications.^[@R55],\ [@R56]^ It is well-known that CO's targets are largely in the mitochondria.^[@R57]^ Thus, we hypothesized that targeting CO release to mitochondria would lead to significant anti-inflammatory and anti-apoptotic effects. Therefore, we next compared administering a combination of the TPP-conjugated CO-prodrugs (**21b**+**22b**) to their counterparts without the TPP unit and ability to enrich (**21a** + **22a**). Mice were treated with **21a** and **22a** or **21b** and **22b**. Controls received equivalent volumes of DMSO as the vehicle. Mice were administered APAP followed 4 h later with **21b** followed 3 min later by **22b** at 4 mg/kg, i.v. or 0.4 mg/kg, i.v. in separate groups. These animals were compared to those that received **21a** plus **22a** using identical treatment regimens. Serum and liver tissue were collected 24 h later and analyzed for serum alanine aminotransferase (ALT) as a measure of liver injury and immunostaining of liver sections for indices of cell death (TUNEL) and architectural changes \[Hemotoxylin and Eosin (H&E)\]. Both **21a** plus **22a** or **21b** plus **22b** showed significantly lower serum ALT levels relative to DMSO vehicle-treated animals in response to APAP ([Figure 4](#F4){ref-type="fig"}), which is consistent with literature reported protective effects of CO.^[@R53]^ At the higher 4 mg/kg dose the reduction in ALT achieved with **21a** and **22a** was 58%. In contrast those animals treated with the TTP-conjugates **21b** and **22b** known to enrich in the mitochondria, the reduction in serum ALT levels was \>95%. At a 10-fold lower dose (0.4 mg/kg), treatment with the TPP conjugates (**21b** and **22b**) resulted in 55% reduction in serum ALT levels, compared to the non-TPP conjugated compounds (**21a** and **22a**) which had no effect on APAP-induced ALT levels. It should also be noted that treatment with **21b** and **22b** increased carboxyhemoglobin levels, which is an important pharmacokinetic indicator for CO presence in the circulation ([Figure 4b](#F4){ref-type="fig"}). Finally, histological staining analyses of the livers from these mice corroborated the serum ALT data showing less cell death as measured by TUNEL and H&E in those animals treated wtih the **21b** and **22b** pair ([Figure 4c--h](#F4){ref-type="fig"}). Collectively, these results clearly show that TPP conjugation enhances local delivery of CO in a dose-dependent fashion that provides potent heaptoprotection. It should be noted that the molecular weights of the TPP conjugates (**21b**, **22b**) are nearly twice that of the parent compounds (**21a**, **22a**). Thus, the same dose based on weight is half the dose when considering the molarity for the TPP conjugates. Taken together, these results demonstrate in part the proof of principle of the "enrich and release" concept *in vivo* for effective delivery of CO to impart tissue cytoprotection.

Conclusions {#S9}
===========

In conclusion, in targeted therapy, there is a strong need for the development of new chemistry to achieve selective delivery to complement existing ones. In this study, we developed and tested a new concept and platform approach, which relies on concentration-sensitive chemistry to allow for selective drug release upon enrichment. This is achieved by taking advantage of reaction kinetics, that allows for accelerated cleavage at an elevated concentration. Such an approach will may prove very useful in delivering small molecules through targeting including the use of antibody drug conjugates and receptor-mediated drug delivery. As a result, the delivery is not limited to the cell surface and can be used for sub-cellular delivery, with enriched concentrations, which could not be achieved by ADC based delivery. Collectively, we describe a method that could be leveraged for biologic and medicinal efforts in treating disease. These compounds may be very useful therapeutics for the treatment of cancer and acute liver injury.

Data availability {#S10}
-----------------

Additional details on methods and compound characterizations are available in the [Supplementary Information](#SD1){ref-type="supplementary-material"}. [Supplementary figures](#SD1){ref-type="supplementary-material"} include ^1^H NMR spectra of **21a** at different temperatures ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}), schematic representations of the reaction between tetrazine **10** and alkyne **2** ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}), studies of reaction kinetics ([Supplementary Figs. 4--6](#SD1){ref-type="supplementary-material"}), CO-myoglobin assay ([Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}), cytotoxicity assay ([Supplementary Figs. 9 and 10](#SD1){ref-type="supplementary-material"}), Elisa assay ([Supplementary Fig. 11](#SD1){ref-type="supplementary-material"}) and NMR spectra of all synthesized compounds. [Supplementary tables](#SD2){ref-type="supplementary-material"} include results of studies on reaction kinetics ([Supplementary Tables 1--3](#SD2){ref-type="supplementary-material"}), stability tests ([Supplementary Table 4](#SD2){ref-type="supplementary-material"}) and computational studies ([Supplementary Table 5](#SD2){ref-type="supplementary-material"}) data.
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![Schematic illustration of the concept of enrichment-triggered prodrug activation\
The two components would not click with each other during circulation at low concentrations. Upon enrichment in the targeted area, the significant increase in local concentrations leads to enhanced reaction rate, and thereby the drug is released in the targeted area.](nihms956045f1){#F1}

![The cytotoxicity of click and release pairs in Hela cells\
The click pairs (**9** + **3b**) with TPP conjugation showed more pronounced cytotoxicity as compared to the ones without TPP conjugation (**6** + **3a**) as designed. The Hela cells were incubated with different concentrations of Dox-prodrug **6** and alkyne trigger **3a** or TPP -Dox-prodrug **9** and TPP- alkyne trigger **3b** for 48h. a) Prodrugs with 10 μM the respective trigger; b) prodrugs with 20 μM of the respective trigger; The cytotoxicity was evaluated by a crystal violet assay. Results represent mean±SD of n =4. \*p\<0.05, \*\*p\<0.001 vs without TPP conjugation.](nihms956045f2){#F2}

![Fluorescent imaging studies of the click reaction between 21 and 22 in Raw264.7 cells\
The click reaction between **21b** and **22b** resulted in dose-dependent increase in fluorescent intensity, which tracked that of a fluorescent mitochondrion-tracker, while the control click reaction between **21a** and **22a** only showed negligible fluorescence. Images a, b, c and d show the results from the click reaction between compound **21** and **22**. a) RAW 264.7 cells treated with **22a** (1 μM) and **21a** (1 μM); b) RAW 264.7 cells treated with **22a** (5 μM) and **21a** (5 μM); c) RAW 264.7 cells treated with **22b** (1 μM) and **21b** (1 μM); d) RAW 264.7 cells treated with **22b** (5 μM) and **21b** (5 μM). Images e, f, g and h are confocal images of RAW 264.7 cells treated with compound **21b** (5 μM), **22b** (2.5 μM) and MT-deep red (50 nM). e) Bright field; f) Red channel; g) DAPI channel; h) Merged images of e), f) and g). Images represent 3 fields of view from 3 independent experiments in triplicate.](nihms956045f3){#F3}

![CO prodrugs protect against acute liver failure\
**a.** The effect of CO prodrugs on APAP induced liver injury. Mice were treated with APAP (300 mg/kg, i.p.) followed by administration of compounds **21a** plus **22a** or the **21b** and **22b** (4 (high) or 0.4 (low) mg/kg, i.v.) or DMSO. Three minutes separated the first and second injections. Serum ALT levels were determined 24h after APAP. Results represent mean±SD of n = 6--8 animals/group. \*\*p\<0.03, \*p\<0.001 vs DMSO. **b.** COHb levels over time after administration of **21b** plus **22b** (4 mg/kg, i.v.). Results represent mean±SD of 3 mice/time point. \*p\<0.005 vs baseline. **c--e.** Hemotoxylin and Eosin staining of liver sections from mice treated as in **a** with **21b** and **22b** at 4 mg/kg, i.v. Dotted sections designate dead/dying tissue. **f--h.** TUNEL staining of liver sections from the same animals in **c--e.** Brown staining indicates cell death. All images are representative 4--5 fields of view from at least 3 animals/group.](nihms956045f4){#F4}

###### 

Chemical structure of CCR systems and evaluation of the reaction kinetics of the CCR system. All reactions were conducted in PBS containing 10% DMSO.

  -------- ---------------- -------------- ---------------------------------- --------------------------------- --------------
  **5**    **1**            0.25± 0.06     1.9± 0.4                           0.029± 0.006                      60± 6 (48 h)
  **2**    0.0075± 0.0009   0.021± 0.005   [\*](#TFN1){ref-type="table-fn"}   90± 5 (20 h)                      
  **3b**   0.042± 0.012     0.14± 0.04     0.16±0.04                          90 ±3 (16 h)                      
  **6**    **1**            0.36± 0.07     2.1 ±0.4                           [Δ](#TFN2){ref-type="table-fn"}   20±5 (48 h)
  **2**    0.0078±0.0009    0.025±0.006    [\*](#TFN1){ref-type="table-fn"}   85±5 (21 h)                       
  **3b**   0.065±0.013      0.19±0.04      0.20±0.04                          80±5 (18 h)                       
  **3a**   0.061±0.013      0.17±0.05      0.21±0.04                          80±5 (19 h)                       
  **9**    **3b**           0.091±0.013    0.25±0.05                          0.22±0.05                         78±6 (18 h)
  -------- ---------------- -------------- ---------------------------------- --------------------------------- --------------

not detectable because of the slow second order reaction and fast lactonization reaction. No intermediates were observed.

not detectable because of Dox decomposition in PBS. (n = 3, p= 0.95).

###### 

IC~50~ in Hela cell line (n = 3, p = 0.95)

  Compounds                          IC~50~ (μM)
  ---------------------------------- -------------
  Dox-prodrug **6**                  \>100
  Alkyne **1**                       \>100
  Alkyne **3b**                      \>50
  Dox                                1.0±0.2
  Dox-prodrug **6** + 50 μM **1**    1.5±0.3
  Dox-prodrug **6** + 100 μM **1**   1.3±0.2
  Dox-prodrug **6** + 50 μM **3b**   2.3±0.4
  Tetrazine **4+** 100 μM **1**      \>100

###### 

The structure of TPP-conjugated cyclopentadienone-alkyne pairs and the kinetics data.

  --------- --------- -------------
  **21a**   **22a**   0.14 ± 0.02
  **21b**   **22b**   0.20 ± 0.03
  --------- --------- -------------
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